Despite Positive DYNE-101 Data, Oppenheimer Steps to the Sidelines on Dyne Therapeutics Due to Valuation and Safety Caution

Oppenheimer downgrades Dyne Therapeutics to Perform from Outperform, maintaining $13 price target. New Phase 1/2 data shows promise, but valuation concerns prompt caution.